a synthetic adjuvant to enhance and expand immune responses to influenza vaccines合成佐剂来增强和扩大对流感疫苗的免疫反应.pdfVIP

A Synthetic Adjuvant to Enhance and Expand Immune Responses to Influenza Vaccines 1. 1. 1 1 1 Rhea N. Coler , Susan L. Baldwin , Narek Shaverdian , Sylvie Bertholet , Steven J. Reed , Vanitha S. 1 2 2 2 2 1 Raman , Xiuhua Lu , Joshua DeVos , Kathy Hancock , Jacqueline M. Katz , Thomas S. Vedvick , 1 3 3 1,3 Malcolm S. Duthie , Christopher H. Clegg , Neal Van Hoeven , Steven G. Reed * 1 Infectious Disease Research Institute, Seattle, Washington, United States of America, 2 National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America, 3 Immune Design Corporation, Seattle, Washington, United States of America Abstract Safe, effective adjuvants that enhance vaccine potency, including induction of neutralizing Abs against a broad range of variant strains, is an important strategy for the development of seasonal influenza vaccines which can provide optimal protection, even during seasons when available vaccines are not well matched to circulating viruses. We investigated the safety and ability of Glucopyranosyl Lipid Adjuvant-Stable Emulsion (GLA-SE), a synthetic Toll-like receptor (TLR)4 agonist formulation, to adjuvant FluzoneH in mice and non-human primates. The GLA-SE adjuvanted Fluzone vaccine caused no adverse reactions, increased the induction of T helper type 1 (TH1)-biased cytokines such as IFNc, TNF and IL-2, and broadened